Risk of cancer in relatives of patients with myotonic dystrophy: A population-based cohort study

European Journal of Neurology

Volumn 21, Issue 9, 2014, Pages 1192-1197

  Lund, M ^a   Diaz, L J ^a   Gortz S ^a   Feenstra, B ^a   Duno, M ^b   Juncker, I ^c   Eiberg, H ^d   Vissing, J ^b   Wohlfahrt, J ^a   Melbye, M ^a,e  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Epidemiology; Family cancer risk; Myotonic dystrophy

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DENMARK; FEMALE; FIRST DEGREE RELATIVE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOTONIC DYSTROPHY; POPULATION RESEARCH; PRIORITY JOURNAL; AGE; AGED; FACTUAL DATABASE; FAMILY; FAMILY HEALTH; HEALTH CARE PLANNING; MIDDLE AGED; NEOPLASMS; RISK FACTOR;

ADULT; AGE FACTORS; AGED; COHORT STUDIES; COMMUNITY HEALTH PLANNING; DATABASES, FACTUAL; DENMARK; FAMILY; FAMILY HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; NEOPLASMS; RISK FACTORS;

EID: 84905052676     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12466     Document Type: Article

References (29)

1. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry 2010; 81: 358-367.
2. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 69: 385.
3. Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255: 1256-1258.
4. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255: 1253-1255.
5. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864-867.
6. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11: 891-905.
7. Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT III, Greene MH. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 2009; 20: 2009-2020.
8. Velazquez-Martin JP, Pavlin CJ, Simpson ER. Association between uveal melanoma and myotonic dystrophy: a series of 3 cases. JAMA Ophthalmol 2013; 131: 246-249.
9. Gadalla SM, Lund M, Pfeiffer RM, et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011; 306: 2480-2486.
10. Mohamed S, Pruna L, Kaminsky P. Increasing risk of tumors in myotonic dystrophy type 1. Presse Med 2013; 42: e281-e284.
11. Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM. Increased cancer risks in myotonic dystrophy. Mayo Clin Proc 2012; 87: 130-135.
12. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280: 737-741.
13. Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012; 11: 847-859.
14. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093.
15. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010; 220: 152-163.
16. Kamsteeg EJ, Kress W, Catalli C, et al. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet 2012; 20: 1203-1208.
17. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42-45.
18. Sundhedsstyrelsen (Danish Health and Medicines Authority). Det moderniserede Cancerregister - metode og kvalitet [Online]; 2009.
19. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006; 15(Spec No 2): R162-R169.
20. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006; 29: 259-277.
21. Kalsotra A, Xiao X, Ward AJ, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA 2008; 105: 20333-20338.
22. Xu X, Yang D, Ding JH, et al. ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 2005; 120: 59-72.
23. Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene 2013; doi: 10.1038/onc.2013.533. (epub ahead of print).
24. Karni R, Stanchina ED, Lowe SW, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193.
25. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
26. Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417-427.
27. Shapiro IM, Cheng AW, Flytzanis NC, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
28. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-25.
29. Lund M, Diaz LJ, Ranthe MF, et al. Cardiac involvement in myotonic dystrophy: a nationwide cohort study. Eur Heart J 2014; PMID: 24742887 (Epub ahead of print).